Literature DB >> 25004078

Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans.

Megan M Yardley1, Michael Neely, Nhat Huynh, Liana Asatryan, Stan G Louie, Ronald L Alkana, Daryl L Davies.   

Abstract

Ivermectin (IVM), an FDA approved anthelmintic agent, can significantly reduce ethanol intake in mice following acute administration. The current study evaluates the sustainability and safety of multiday IVM administration in reducing 10% v/v ethyl alcohol (10E) intake in mice at a dose shown to be safe in humans. We tested the effect of 10-day administration of IVM (3.0 mg/kg/day; intraperitoneally) on reducing 10E intake in C57BL/6J mice using a 24-h, two-bottle choice paradigm. On the 10th day of IVM administration, mice were sacrificed at 0, 0.5, 2, 8, 32, 48, and 72 h after injection. Brain tissue and plasma samples were collected and analyzed using liquid chromatography with tandem mass spectrometry (LC-MS/MS). Analysis of variance (ANOVA) was used to assess the effect of 10-day IVM administration on 10E intake, 10E preference, water intake, and total fluid intake with Dunnett's multiple comparison post-hoc test. Individual Student's t-tests were also used to further quantify changes in these dependent variables. IVM significantly decreased 10E intake over a 9-day period (P<0.01). Pre-IVM 10E intake was 9.1±3.2 g/kg/24 h. Following the 9th day of IVM injections, intake dropped by almost 30% (P<0.05). IVM had no effect on total water intake or mouse weight throughout the study; however, there was a significant decrease in both preference for 10E (P<0.01) and total fluid intake (P<0.05). Multiday administration of IVM significantly reduces 10E intake and preference in animals without causing any apparent adverse effects at a dose shown to be safe in humans.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25004078      PMCID: PMC4126080          DOI: 10.1097/WNR.0000000000000211

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  23 in total

1.  Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.

Authors:  Cynthia A Guzzo; Christine I Furtek; Arturo G Porras; Cong Chen; Robert Tipping; Coleen M Clineschmidt; David G Sciberras; John Y K Hsieh; Kenneth C Lasseter
Journal:  J Clin Pharmacol       Date:  2002-10       Impact factor: 3.126

2.  The genetics of mouse behavior in novel situations.

Authors:  G E McCLEARN
Journal:  J Comp Physiol Psychol       Date:  1959-02

3.  Contribution of P2X4 receptors to ethanol intake in male C57BL/6 mice.

Authors:  Letisha R Wyatt; Deborah A Finn; Sheraz Khoja; Megan M Yardley; Liana Asatryan; Ronald L Alkana; Daryl L Davies
Journal:  Neurochem Res       Date:  2014-03-27       Impact factor: 3.996

Review 4.  Research activities related to treatment of alcoholism.

Authors:  D A Rodgers
Journal:  Compr Psychiatry       Date:  1966-02       Impact factor: 3.735

5.  Ethanol consumption by C57BL/6 mice: influence of gender and procedural variables.

Authors:  L D Middaugh; B M Kelley; A L Bandy; K K McGroarty
Journal:  Alcohol       Date:  1999-04       Impact factor: 2.405

Review 6.  Ivermectin 20 years on: maturation of a wonder drug.

Authors:  Timothy G Geary
Journal:  Trends Parasitol       Date:  2005-08-26

7.  Voluntary consumption of ethanol in 15 inbred mouse strains.

Authors:  J K Belknap; J C Crabbe; E R Young
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Voluntary ethanol consumption in 22 inbred mouse strains.

Authors:  Naomi Yoneyama; John C Crabbe; Matthew M Ford; Andrea Murillo; Deborah A Finn
Journal:  Alcohol       Date:  2008-03-20       Impact factor: 2.405

Review 9.  Ivermectin: 25 years and still going strong.

Authors:  S Omura
Journal:  Int J Antimicrob Agents       Date:  2007-11-26       Impact factor: 5.283

10.  Hybrid mice as genetic models of high alcohol consumption.

Authors:  Y A Blednov; A R Ozburn; D Walker; S Ahmed; J K Belknap; R A Harris
Journal:  Behav Genet       Date:  2009-10-02       Impact factor: 2.965

View more
  7 in total

Review 1.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

2.  Functional characterization of neurotransmitter activation and modulation in a nematode model ligand-gated ion channel.

Authors:  Stephanie A Heusser; Özge Yoluk; Göran Klement; Erika A Riederer; Erik Lindahl; Rebecca J Howard
Journal:  J Neurochem       Date:  2016-05-25       Impact factor: 5.372

3.  Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder.

Authors:  Nhat Huynh; Natalie Arabian; Anna Naito; Stan Louie; Michael W Jakowec; Liana Asatryan; Daryl L Davies
Journal:  Neuropharmacology       Date:  2016-09-15       Impact factor: 5.250

4.  A novel pharmacotherapy approach using P-glycoprotein (PGP/ABCB1) efflux inhibitor combined with ivermectin to reduce alcohol drinking and preference in mice.

Authors:  Joshua Silva; Sheraz Khoja; Liana Asatryan; Eunjoo Pacifici; Daryl L Davies
Journal:  Alcohol       Date:  2020-04-08       Impact factor: 2.405

5.  Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus).

Authors:  Andrea S Zanetti; Sumanth K Putta; Donald B Casebolt; Stan G Louie
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-11-01       Impact factor: 1.232

Review 6.  Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders.

Authors:  Sheraz Khoja; Nhat Huynh; Alicia M P Warnecke; Liana Asatryan; Michael W Jakowec; Daryl L Davies
Journal:  Psychopharmacology (Berl)       Date:  2018-03-02       Impact factor: 4.530

7.  Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder.

Authors:  Megan M Yardley; Nhat Huynh; Kathleen E Rodgers; Ronald L Alkana; Daryl L Davies
Journal:  Alcohol       Date:  2015-05-29       Impact factor: 2.405

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.